Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Curcuminoids, the active polyphenolic compounds in turmeric (Curcuma longa), have been studied for their anti-inflammatory and antioxidant properties. There is a growing body of scientific evidence supporting their use in the management of colitis, particularly ulcerative colitis. Several randomized controlled trials (RCTs) and systematic reviews have indicated that curcumin supplementation, often as an adjunct to conventional therapy (such as mesalamine), can help maintain remission and reduce symptoms in patients with ulcerative colitis. Proposed mechanisms include suppression of nuclear factor-kappa B (NF-κB) signaling, reduction of pro-inflammatory cytokines, and preservation of the intestinal epithelial barrier.

A 2006 double-blind, placebo-controlled trial published in Clinical Gastroenterology and Hepatology demonstrated that patients receiving curcumin in addition to standard therapy had significantly lower relapse rates compared to placebo. More recent meta-analyses have confirmed these findings, though some note the need for larger, high-quality studies and standardization of curcumin formulations due to issues with bioavailability.

While turmeric has a long history of traditional use for gastrointestinal complaints, the specific application of isolated curcuminoids for colitis is primarily supported by modern scientific research. Overall, the evidence base is reasonably strong for adjunctive use, but curcuminoids are not considered a replacement for standard medical therapies.

More about Curcuminoids
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Curcuminoids

Products containing Curcuminoids